Tags

Type your tag names separated by a space and hit enter

BACE1 in Alzheimer's disease.
Clin Chim Acta. 2012 Dec 24; 414:171-8.CC

Abstract

Targeting BACE1 (β-site APP cleaving enzyme 1 or β-secretase) is the focus of Alzheimer's disease (AD) research because this aspartyl protease is involved in the abnormal production of β amyloid plaques (Aβ), the hallmark of its pathophysiology. Evidence suggests that there is a strong connection between AD and BACE1. As such, strategies to inhibit Aβ formation in the brain should prove beneficial for AD treatment. Aβ, the product of the large type1 trans-membrane protein amyloid precursor protein (APP), is produced in a two-step proteolytic process initiated by BACE1 (β-secretase) and followed by γ-secretase. Due to its apparent rate limiting function, BACE1 appears to be a prime target to prevent Aβ generation in AD. Following its discovery, the BACE1 has been cloned, its structure solved, novel physiologic substrates discovered and numerous inhibitors developed. This review focuses on elucidating the role of BACE1 to facilitate drug development in the treatment of AD.

Authors+Show Affiliations

Department of Biochemistry, Bharathidasan University, Trichy 24, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22926063

Citation

Sathya, M, et al. "BACE1 in Alzheimer's Disease." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 414, 2012, pp. 171-8.
Sathya M, Premkumar P, Karthick C, et al. BACE1 in Alzheimer's disease. Clin Chim Acta. 2012;414:171-8.
Sathya, M., Premkumar, P., Karthick, C., Moorthi, P., Jayachandran, K. S., & Anusuyadevi, M. (2012). BACE1 in Alzheimer's disease. Clinica Chimica Acta; International Journal of Clinical Chemistry, 414, 171-8. https://doi.org/10.1016/j.cca.2012.08.013
Sathya M, et al. BACE1 in Alzheimer's Disease. Clin Chim Acta. 2012 Dec 24;414:171-8. PubMed PMID: 22926063.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BACE1 in Alzheimer's disease. AU - Sathya,M, AU - Premkumar,P, AU - Karthick,C, AU - Moorthi,P, AU - Jayachandran,K S, AU - Anusuyadevi,M, Y1 - 2012/08/20/ PY - 2012/06/22/received PY - 2012/08/08/revised PY - 2012/08/15/accepted PY - 2012/8/29/entrez PY - 2012/8/29/pubmed PY - 2013/5/18/medline SP - 171 EP - 8 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin Chim Acta VL - 414 N2 - Targeting BACE1 (β-site APP cleaving enzyme 1 or β-secretase) is the focus of Alzheimer's disease (AD) research because this aspartyl protease is involved in the abnormal production of β amyloid plaques (Aβ), the hallmark of its pathophysiology. Evidence suggests that there is a strong connection between AD and BACE1. As such, strategies to inhibit Aβ formation in the brain should prove beneficial for AD treatment. Aβ, the product of the large type1 trans-membrane protein amyloid precursor protein (APP), is produced in a two-step proteolytic process initiated by BACE1 (β-secretase) and followed by γ-secretase. Due to its apparent rate limiting function, BACE1 appears to be a prime target to prevent Aβ generation in AD. Following its discovery, the BACE1 has been cloned, its structure solved, novel physiologic substrates discovered and numerous inhibitors developed. This review focuses on elucidating the role of BACE1 to facilitate drug development in the treatment of AD. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/22926063/BACE1_in_Alzheimer's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(12)00410-X DB - PRIME DP - Unbound Medicine ER -